Overview

Subconjunctival Humira for Boston Keratoprosthesis

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.

Phase:

PHASE1

Details

Lead Sponsor:

Massachusetts Eye and Ear Infirmary

Treatments:

Adalimumab